Navigation Links
EnVivo Pharmaceuticals Announces Executive Appointment
Date:9/26/2007

Dr. Dana C. Hilt Named SVP, Clinical Development & Chief Medical Officer

WATERTOWN, Mass., Sept. 26 /PRNewswire/ -- EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, today announced the appointment of Dr. Dana C. Hilt as Senior Vice President and Chief Medical Officer. He will be responsible for coordinating all pre-clinical and clinical development activities of EnVivo's growing pipeline.

Dr. Hilt, 55, previously served as Senior Vice President, Clinical Research and Medical Affairs & Chief Medical Officer for Critical Therapeutics in Lexington, Massachusetts. Dr. Hilt is a distinguished neurologist with extensive drug development experience from his tenures at Amgen, Guilford Pharmaceuticals and Ascend Therapeutics. In addition, he has held both scientific and professorial positions with the University of Southern California School of Medicine, the National Institutes of Health and the University of Maryland School of Medicine where he was a clinical Associate Professor in the department of Neurology. At the beginning of his career, he was a Resident Fellow in Neurology at the Johns Hopkins University School of Medicine and interned at Harvard University Medical School.

Dr. Hilt is a member of the American Academy of Neurology, Movement Disorders Society, American Society for Experimental Neurotherapeutics, American Association for the Advancement of Science, Society for Neuroscience and Endocrine Society. He is the author of over 50 publications. Dr. Hilt received his Bachelor of Science Degree in Chemistry (with Distinction) from the University of Maine and an M.D. from the Tufts University School of Medicine.

"Given the continuing growth of EnVivo's pre-clinical and clinical programs in the field of neuro-degenerative diseases, Dana brings critically important skills to the management team. His deep expertise in drug development will be of increasing importance as we progress our pipeline and are seeking to further broaden our pipeline in the next two years," said Kees Been, President and Chief Executive Officer.

EnVivo Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing drugs for central nervous system (CNS) disorders including, Alzheimer's disease, Parkinson's disease, Huntington's disease and Spino Cerebellar Ataxias. The company's lead programs include a Nicotinic Acetylcholine Receptor Agonist Program (alpha-7) for Alzheimer's disease and Schizophrenia, a Histone Deacetylase (HDAC) program for Huntington's disease, EVP2442 program for neuron-protection and the PDE10 inhibitor and gamma- secretase modulator programs. For more information see http://www.envivopharma.com


'/>"/>
SOURCE EnVivo Pharmaceuticals, Inc.,
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... ... May 20, 2017 , ... CNSDose ... lengthy trial and error process by finding the right antidepressant faster. CNSDose ... the doctor-patient relationship through a personalized approach to treatment. , A ...
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. Ralph Mobbs of ... Prince Of Wales Private Hospital. The procedure was performed on a 46-year-old male ... conservative treatments prior to undergoing surgery. , The AxioMed viscoelastic disc is a ...
(Date:5/18/2017)... , ... May 17, 2017 , ... NDA Partners Chairman ... and former CEO of Eurofins Advantar Laboratories and President of Pharmaceutical Development Business Unit ... his position at Eurofins and Cardinal Health, he was former Chief Operating Officer at ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... optimization firm for the life sciences and healthcare industries, is honored that ... for Medical Devices conference in Brussels, Belgium. , Crowley played a crucial role ...
Breaking Biology Technology:
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
Breaking Biology News(10 mins):